Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 02, 2023 08:28 ET | Source: Advanced Catheter Therapies

Occlusion Perfusion Catheter Demonstrates Superior Performance in PAD Drug Delivery

Researchers successfully demonstrate the delivery of liquid sirolimus into the arterial wall using the OPC, which can also be used for paclitaxel BTK.
August 31, 2023 10:38 ET | Source: AI Therapeutics, Inc.

AI Therapeutics Announces Initiation of a Phase 2 Clinical Trial of LAM-001 for Treatment of Pulmonary Arterial Hypertension (PAH)

GUILFORD, Conn., Aug. 31, 2023 (GLOBE NEWSWIRE) -- AI Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for rare diseases, announced today the initiation...
November 07, 2022 08:10 ET | Source: Global Market Insights Inc.

Drug-eluting Balloon Catheters Market to hit USD 1 billion by 2030, says Global Market Insights Inc.

Selbyville, Delaware, Nov. 07, 2022 (GLOBE NEWSWIRE) -- The global drug-eluting balloon catheters market value is poised to surpass USD 1 billion by 2030, according to a new research report by...
April 13, 2022 07:15 ET | Source: Global Market Insights Inc.

Drug-Eluting Balloon Catheters Market to hit USD 916 Million by 2028, Says Global Market Insights Inc.

Selbyville, Delaware, April 13, 2022 (GLOBE NEWSWIRE) -- Global drug-eluting balloon catheters market value is anticipated to reach USD 916 million by 2028, according to a new research report by...
September 29, 2020 19:00 ET | Source: Fior Markets

Global Drug-Eluting Bioabsorbable Stents Market Is Expected to Reach USD 579.87 Million by 2027 : Fior Markets

Newark, NJ, Sept. 29, 2020 (GLOBE NEWSWIRE) -- As per the report published by Fior Markets, the global drug-eluting bioabsorbable stents market is expected to grow from USD 393.31 million in 2019...
September 05, 2018 08:00 ET | Source: Palvella Therapeutics

Palvella Therapeutics Appoints Rare Disease Senior Executive Elaine J. Heron, PhD to Board of Directors

Wayne, PA, Sept. 05, 2018 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc., a rare disease biopharmaceutical company focused on developing and commercializing pathogenetically targeted therapies for...